1 Min Read
Feb 16 (Reuters) - Windtree Therapeutics Inc
* Windtree Therapeutics - aerosolized KL4 surfactant reduces lung inflammation and improves survival in high-pathogen avian influenza preclinical study Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.